Study of MRG007 for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called MRG007 combined with other treatments for people with advanced colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced colorectal cancer that has spread or cannot be removed by surgery.
- You need to have a tumor sample available for testing, or be willing to have a new biopsy.
- You must be well enough to be up and about (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- You cannot have a specific type of colorectal cancer called MSI-high or dMMR.
- You cannot have other active cancers, serious heart disease, or unstable blood clots.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests a new drug called LPM6690176 combined with chemotherapy and Avastin (bevacizumab) for people with metastatic colorectal cancer that has a RAS mutation. It may be an option for those who haven't had treatment for their advanced cancer or have already tried one line of therapy.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
Hear when a new Advanced Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.